A Clinical Guide for Discussing Marijuana With Patients in the Age of Legalization
Clinicians need motivational interviewing skills, evidence-based informed consent practices, and updated knowledge to navigate patient conversations about marijuana in an era of changing laws and attitudes.
Quick Facts
What This Study Found
As medical and recreational marijuana laws evolve, clinicians face a challenging communication environment. Patients may overestimate marijuana's benefits based on media coverage, while providers may lack current knowledge about evidence-based indications and risks.
The article offers practical guidance for clinicians: maintaining motivational interviewing skills (rather than lecturing or confronting patients about use), providing evidence-based informed consent that honestly addresses both potential benefits and known risks, and recognizing that the provider-patient relationship is the foundation for productive conversations about marijuana.
The authors emphasize that misconceptions exist on both sides. Some patients believe marijuana is harmless and helps everything, while some providers dismiss all potential medical applications. Neither position reflects the evidence.
Key Numbers
No specific quantitative data. The article addresses the qualitative challenge of clinical communication about a rapidly evolving topic.
How They Did This
Clinical guidance article reviewing communication strategies, evidence-based approaches, and practical considerations for provider-patient conversations about marijuana.
Why This Research Matters
The gap between patient expectations and clinical evidence creates a communication challenge that directly affects care quality. Clinicians who can discuss marijuana openly and knowledgeably build trust and improve outcomes, while those who avoid the topic or dismiss it lose opportunities to guide patients toward safer practices.
The Bigger Picture
Medical education has not kept pace with marijuana policy changes. Most clinicians receive minimal training on cannabinoids, creating a knowledge gap that this kind of practical guidance aims to fill. As more states and countries legalize, the need for evidence-based clinical communication about marijuana grows.
What This Study Doesn't Tell Us
Guidance article without systematic evidence review. Recommendations are based on clinical experience and available evidence rather than tested interventions. The rapidly changing policy landscape may make some guidance outdated quickly.
Questions This Raises
- ?Would standardized medical education on cannabinoids improve clinical conversations?
- ?How do patient outcomes differ when providers discuss marijuana openly versus avoid the topic?
- ?What communication strategies are most effective?
Trust & Context
- Key Stat:
- Misconceptions about marijuana exist on both patient and provider sides
- Evidence Grade:
- Clinical guidance based on expert experience and available evidence, not a systematic review or primary research.
- Study Age:
- Published in 2016. Marijuana legalization has expanded significantly since, making these communication challenges more widespread.
- Original Title:
- Practical Aspects of Discussing Marijuana in a New Era.
- Published In:
- Journal of psychiatric practice, 22(6), 471-477 (2016)
- Authors:
- Lenoue, Sean R, Wongngamnit, Narin, Thurstone, Christian(5)
- Database ID:
- RTHC-01207
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How should doctors talk to patients about marijuana?
This article recommends using motivational interviewing (asking questions rather than lecturing), providing honest evidence-based information about both benefits and risks, and maintaining an open, non-judgmental dialogue.
What misconceptions do patients and doctors have?
Some patients believe marijuana is harmless and treats everything, while some providers dismiss all medical applications. Both positions are inconsistent with the evidence, which shows specific benefits and specific risks.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- medical-card-worth-it-2026-benefits-costs
Cite This Study
https://rethinkthc.com/research/RTHC-01207APA
Lenoue, Sean R; Wongngamnit, Narin; Thurstone, Christian. (2016). Practical Aspects of Discussing Marijuana in a New Era.. Journal of psychiatric practice, 22(6), 471-477.
MLA
Lenoue, Sean R, et al. "Practical Aspects of Discussing Marijuana in a New Era.." Journal of psychiatric practice, 2016.
RethinkTHC
RethinkTHC Research Database. "Practical Aspects of Discussing Marijuana in a New Era." RTHC-01207. Retrieved from https://rethinkthc.com/research/lenoue-2016-practical-aspects-of-discussing
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.